Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. Sells 6,500 Shares

Edwards Lifesciences Co. (NYSE:EW) VP Donald E. Bobo, Jr. sold 6,500 shares of Edwards Lifesciences stock in a transaction on Thursday, February 13th. The stock was sold at an average price of $75.75, for a total transaction of $492,375.00. Following the transaction, the vice president now directly owns 46,936 shares in the company, valued at approximately $3,555,402. This represents a 12.16 % decrease in their ownership of the stock. The sale was disclosed in a filing with the Securities & Exchange Commission, which is accessible through this link.

Edwards Lifesciences Stock Up 0.2 %

Shares of EW stock opened at $75.96 on Friday. Edwards Lifesciences Co. has a 52-week low of $58.93 and a 52-week high of $96.12. The stock has a market cap of $44.80 billion, a price-to-earnings ratio of 10.96, a PEG ratio of 3.64 and a beta of 1.10. The firm’s 50-day moving average is $72.51 and its 200-day moving average is $69.36. The company has a debt-to-equity ratio of 0.06, a quick ratio of 2.89 and a current ratio of 3.46.

Edwards Lifesciences (NYSE:EW) last released its quarterly earnings data on Tuesday, February 11th. The medical research company reported $0.59 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.55 by $0.04. Edwards Lifesciences had a return on equity of 20.76% and a net margin of 70.82%. Sell-side analysts predict that Edwards Lifesciences Co. will post 2.56 EPS for the current year.

Wall Street Analyst Weigh In

EW has been the topic of several recent analyst reports. Bank of America upgraded Edwards Lifesciences from a “neutral” rating to a “buy” rating and lifted their target price for the stock from $82.00 to $90.00 in a report on Monday, December 16th. Wolfe Research cut Edwards Lifesciences from a “peer perform” rating to an “underperform” rating and set a $60.00 price objective on the stock. in a report on Thursday, January 16th. Sanford C. Bernstein raised Edwards Lifesciences from a “strong sell” rating to a “hold” rating in a research note on Monday, October 28th. Piper Sandler raised their target price on shares of Edwards Lifesciences from $70.00 to $73.00 and gave the stock a “neutral” rating in a report on Wednesday. Finally, Evercore ISI reduced their price target on shares of Edwards Lifesciences from $75.00 to $73.00 and set an “in-line” rating for the company in a report on Wednesday. One analyst has rated the stock with a sell rating, fourteen have issued a hold rating and twelve have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and an average target price of $79.95.

Hedge Funds Weigh In On Edwards Lifesciences

Several large investors have recently modified their holdings of the stock. Crowley Wealth Management Inc. bought a new stake in shares of Edwards Lifesciences during the 4th quarter worth about $26,000. Millstone Evans Group LLC acquired a new stake in Edwards Lifesciences during the fourth quarter worth approximately $29,000. FSA Wealth Management LLC bought a new stake in shares of Edwards Lifesciences during the third quarter worth approximately $30,000. Migdal Insurance & Financial Holdings Ltd. bought a new stake in shares of Edwards Lifesciences during the fourth quarter worth approximately $30,000. Finally, Prospera Private Wealth LLC acquired a new position in shares of Edwards Lifesciences in the third quarter valued at approximately $32,000. 79.46% of the stock is owned by institutional investors.

Edwards Lifesciences Company Profile

Edwards Lifesciences Corporation provides products and technologies for structural heart disease and critical care monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of aortic heart valves under the Edwards SAPIEN family of valves system; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases under the PASCAL PRECISION and Cardioband names.